Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Amazon and Google Launch New Multicloud Networking Service to Boost High-Speed Cloud Connectivity 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Intel Boosts Malaysia Operations with Additional RM860 Million Investment 
TSMC Accuses Former Executive of Leaking Trade Secrets as Taiwan Prosecutors Launch Investigation 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Visa to Move European Headquarters to London’s Canary Wharf 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Taiwan Opposition Criticizes Plan to Block Chinese App Rednote Over Security Concerns 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
